Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 9, 2005

View Archived Issues

PET scans may help predict response to therapy in metastatic breast cancer

Inhaled insulin shows promise as an alternative to subcutaneous insulin in type 1 diabetes

Novartis reflects on Q2 activities

Thymitaq phase III study fails to meet primary endpoint

Phase IIb studies begin for PT-141 for erectile dysfunction

Two more sites join Canadian phase II study of ADH-1

Par terminates amoxicillin partnership with Advancis

Characterization of a novel VRAC inhibitor for heart disease

KBMA vaccines: novel strategy for safe protective immunity

SB-706375: novel nonpeptidic UT receptor antagonist

Antithrombotic activity of DU-176b described in several animal models

Data describing pharmacodynamic profile of TGN-255 presented

Biogen Idec and PDL form collaboration for antibody products

Novel immunomodulatory agents disclosed in recent patents

Novel agents for thrombotic disorders prepared and tested

Novel agents for treating ADHD in early development at PsychoGenics

Novel MRI agents imparted by General Hospital Corporation

Santhera and Takeda to collaborate on idebenone for Friedreich's ataxia

Pozen discontinues MT-100 development in U.S. following FDA review

Pozen submits Trexima NDA for migraine

HIV protease inhibitors have potential efficacy against opportunistic leishmaniasis infections

European orphan drug status recommended for Amplimexon

Rohto to acquire Bayer Yakuhin research center

AstraZeneca and Astex Therapeutics partner on PKB inhibitors for cancer

ISIS-301012 reduces LDL cholesterol in phase I study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...